Showing results (841-850 of 1,038) with videos related to

Sort By:
Pageof 104
Plos One|October 22, 2016
Correction: Environmental DNA Marker Development with Sparse Biological Information: A Case Study on Opossum Shrimp (Mysis diluviana)Kellie J Carim, Kyle R Christianson, Kevin M McKelvey, et al.
International Journal of Cardiology|June 25, 2003
Accuracy of European diagnostic criteria for familial hypertrophic cardiomyopathy in a genotyped populationP Charron, J F Forissier, M E Amara, et al.
Cancer|January 10, 2001
A phase II study of irinotecan in patients with advanced hepatocellular carcinomaE M O'Reilly, K E Stuart, P M Sanz-Altamira, et al.
The American Journal of Physiology|September 1, 1989
Atrial natriuretic factor gene expression in rat ventricle during experimental hypertensionJ J Mercadier, J L Samuel, J B Michel, et al.
Frontiers in Oncology|June 26, 2023
A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanomaSebastian Bauer, James Larkin, F Stephen Hodi, et al.
European Heart Journal|March 21, 1998
Genotype-phenotype correlations in familial hypertrophic cardiomyopathy. A comparison between mutations in the cardiac protein-C and the beta-myosin heavy chain genesP Charron, O Dubourg, M Desnos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2011
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancerKeith T Flaherty, Patricia M Lorusso, Angela Demichele, et al.
Anticancer Research|June 9, 2001
Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancerG B Cook, I E Neaman, J L Goldblatt, et al.
The Oncologist|August 2, 2023
A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid TumorsElena Garralda, Alison M Schram, Philippe L Bedard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2012
The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trialJason J Luke, David R D'Adamo, Mark A Dickson, et al.
Pageof 104